The Food and Drug Administration has authorized early expanded access to a new pill called daraxonrasib, developed by Revolution Medicines, giving patients with advanced pancreatic cancer a chance to receive the experimental treatment while it awaits full regulatory approval, in a move the agency completed just two days after receiving
